SCHEMBL24137789

SCHEMBL24137789

CNc1cc(-c2cnc(NCc3ccccc3)nc2)ccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS2 P35228 1/20 0.51
▸ MEN1 O00255 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ AAK1 Q2M2I8 1/20 0.46
▸ FABP1 P07148 1/20 0.46
▸ FABP6 P51161 1/20 0.46
▸ MAPK14 Q16539 3/20 0.45
▸ VNN1 O95497 2/20 0.43
▸ HDAC6 Q9UBN7 4/20 0.43
▸ HDAC3 O15379 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ HDAC2 Q92769 1/20 0.43
▸ PIK3C3 Q8NEB9 1/20 0.42
▸ HDAC4 P56524 1/20 0.41
▸ PDGFRB P09619 1/20 0.41
▸ PDGFRA P16234 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30596228 0.82 PIK3C3 (0.48) NOS2MEN1ALDH1A1HPGDKMT2A
SCHEMBL24137484 0.82 PIK3C3 (0.48) NOS2MEN1ALDH1A1HPGDKMT2A
SCHEMBL24137801 0.81 VNN1 (0.47) MEN1ALDH1A1HPGDKMT2AFABP1
SCHEMBL25934164 0.81 FYN (0.45) ALDH1A1HPGDPIK3C3CYP1A2CYP3A4
SCHEMBL2480308 0.77 FDPS (0.53) AAK1WNT3A
SCHEMBL19145368 0.70 VNN1 (0.57) NOS2MEN1ALDH1A1HPGDKMT2A
SCHEMBL23405896 0.70 FABP1 (0.54) MEN1ALDH1A1HPGDKMT2AFABP1
SCHEMBL29743851 0.70 FABP1 (0.54) MEN1ALDH1A1HPGDKMT2AFABP1
SCHEMBL1413125 0.69 FABP1 (0.67) MEN1ALDH1A1HPGDKMT2AFABP1
SCHEMBL27099647 0.69 NOS2 (0.47) NOS2MEN1ALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
WO-2021263129-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE PACSIN2, MAP3K20, PHKG1 NOS2 3713/4885MEN1 1528/4885ALDH1A1 4635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback